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Objectives. To assess the prevalence of activated
protein C resistance (APC-R) among healthy subjects
and thromboembolic patients and to determine the
clinical characteristics associated with APC-R.
Design. A prospective study.
Setting. One academic medical centre.
Subjects.91health controls and126 thromboembolic
patients.
Measurements. Patients and control were genotyped
for the factor V Leiden (VaQ506) mutation. The
anticoagulant response of the patient’s plasma to
activated protein C was also determined.
Results. The frequency of APC-R was 3±3% among
healthy control subjects and 22% among thrombotic
Introduction
Thromboembolic disease is a major cause of mortality
and morbidity in the Western world [1]. The frequent
finding of a positive familial history underlies the role
of genetic factors in the genesis of thromboembolism.
Until recently, inherited deficiency of physiological
inhibitors (antithrombin III, protein C, protein S)
accounted for most cases of hereditary thrombo-
philia ; however, the combined incidence of these
deficits accounts for less than 15% of patients
suffering from thromboembolic disease [2]. In 1993,
Dahlba$ ck and colleagues described a family with a
patients of whom 18% were heterozygous and 4%
were homozygous. The mean age at the first throm-
botic event and the severity of thrombotic disease
including the proportion of proximal deep vein
thrombosis and the frequency of lung embolism were
identical among APC-R positive and negative
patients. A family history of thromboembolic disease
was elicited more frequently in APC-R positive than
in APC-R negative patients (57% vs. 22%, P!
0±001). The recurrence rate was higher for APCR-R
positive patients (57% vs. 34%, P!0±05). The
percentage of cases with a factor predisposing to
thrombosis was very similar in APC-R positive (57%)
and negative (68%) patients.
Conclusions. A familial history of thromboembolic
disease and recurrences are significantly more fre-
quent among APC-R positive than APC-R negative
patients.
Keywords : activated protein C resistance, APC-R,
coagulation, deep venous thrombosis, thrombo-
embolism, thrombophilia.
high incidence of thrombosis whose members
displayed a weak plasmatic response to the anti-
coagulant action of activated protein C (APC). This
inherited abnormality was termed activated protein
C resistance (APC-R) [3]. The underlying genetic
defect was characterized as a factor V point mutation
inducing a substitution of an Arg by a Gln at position
506 [4–7]. The mutated factor Va molecule was
referred to factor VaQ506 or factor V Leiden. This
finding contributed to the elucidation of the APC-R
mechanism: APC plays its anticoagulant role,
through serine protease action, by inactivating
factors Va and factor VIIIa. The modification of one
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of the three activated protein-C cleavage sites located
on the heavy chain renders factor V Leiden less
sensitive to inactivation by APC. As factor V
procoagulant activity is left unchanged, the mutation
unbalances the procoagulant and the anticoagulant
properties leading to a hypercoagulable state [3, 5].
APC-R is transmitted in an autosomal dominant
fashion. It was found in 1±6% to 14±7% of healthy
subjects with a higher incidence being reported in
the Northern countries and lower figures in African
and Asian populations [3, 8, 9–13]. Among
thromboembolic patients, the reported prevalence
ranged from 8% to 64% [8, 9, 14–17]. Although
preliminary reports also advocated an increased
incidence of arterial thrombosis linked to mutated
factor V [18–19], large-scale studies ultimately
discarded this association [20–21].
Aside from the epidemiological interest, the de-
tection of thrombophilia in an individual patient
influences the prognosis and possibly the therapy.
These findings prompted us to study the prevalence
of APC-R, along with other thrombophilic factors
and precipitating circumstances, in our thromboem-
bolic population. The aim was to fix the incidence
and the clinical characteristics of APC-R in a Belgian
population. Additionally, we correlated the APC
ratio, determined by coagulation assay, with DNA
analysis of factor V Leiden mutation, in order to
evaluate whether the APC ratio would discriminate
between negative, homozygous and heterozygous
positive APC-R patients.
Patients and methods
Patients with thrombosis and healthy controls
The study population included prospectively 126
patients and 91 healthy volunteers recruited in a
single academic hospital between June 1993 and
September 1995. Twenty-eight patients were
hospitalized while 98 were outpatients. Ninety-one
normal Caucasian individuals (54 women and 37
men) without either personal or familial history of
thrombosis were included as control subjects.
Assays
Blood sampling. Blood was collected through a clean
venipuncture into tubes containing 0±106 trisodium
citrate for coagulation assay and kalium-EDTA
(1±6 mg EDTA}ml blood) for DNA processing. At
blood sampling none of the patients were receiving
any medication that would interfere with the co-
agulation study.
Coagulation assays. Platelet-free plasma was obtained
by centrifugation at 5000 g for 20 min at 4°C and
was stored at ®20°C until required. Protein C and
antithrombin III levels were determined through a
functional test with chromogenic substrates kits
Chromogenix2 on a centrifugal autoanalyser
ACL200 (Instrumentation laboratory, Milan, Italy).
Protein S was analysed by enzyme-linked
immunosorbent assay testing (free protein S) [22].
Lupus anticoagulant was evaluated by three
screening tests (activated recalcification time,
activated partial thromboplastin time (APTT), tissue
thromboplastin inhibition test (TTI ; using Innovin
Ortho thromboplastin) and two confirming methods
involving plasmatic mixture and platelet
neutralization. The anticoagulant response of the
patient’s plasma to APC was determined using the
Coatest APC Resistance kit (Chromogenix, Sweden)
on an ACL 200. Results are expressed at the ratio of
the APTT clotting time of the plasma in the presence
of exogenous APC to the APTT clotting time without
exogenous APC.
DNA amplification and sequencing. DNA was extracted
from peripheral blood leukocytes using a QI Aamp
Blood kit (Qiagen, Germany). The Arg 506-Gln
mutation of the factor V gene resulting from G-A
1691 substitution was detected using digestion by
the restriction enzyme Mnl of the products amplified
by polymerase chain reaction, as described by Bertina
[5], and sequencing was done using a Taq Dye
Deoxy Terminator Cycle Sequencing kit (Applied
Biosystems, CA, USA).
Diagnosis of thromboembolism
Deep venous thrombosis was confirmed by duplex
Doppler ultrasonography or venography. Lung em-
bolism was diagnosed by high-probability lung
scintigraphy according to Pioped criteria or
angiography.
Statistical analysis
Dichotomic values were compared using the v# test
with Yate’s continuity correction. When appropriate,
results were expressed as odds ratios. Multivariate
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analysis was performed using Mantel-Haenszel’s test
after stratification.
Results
Correlation of coagulation APC ratio assay and DNA
testing
Both APC coagulation assay and gene testing were
performed in 91 controls and 108 consecutive
patients with thrombotic disease. Patients were
classified as APC-R negative, heterozygous and
homozygous according to factor-V mutation gene
testing. Considering the controls and the patients
who benefitted from both tests, the median value
(³SD) of the APC ratios were 3±5 (³0±55), 2±25
(³0±5) and 1±5 (³0±27) for APC-R negative, het-
erozygous and homozygous positive subjects, re-
spectively. Data are shown in Fig. 1. When using a
unique cut-off of 2±6 for all cases, the sensitivity is
79% and the specificity, 96%. If separate cut-offs are
used according to sex and current hormonal therapy
as proposed by others [23; 2±8 for men, 3±0 for
women without oral contraception and 2±5 for
women with oral contraception], the sensitivity is
84% and the specificity 95%.
Prevalence of APC resistance in healthy controls
Among 91 controls with a mean age of 28 years
(range, 20 to 64), the prevalence of APC resistance
was 3±3% including only heterozygous factor V
mutation (Table 1).
Fig. 1 Controls and patients were
classified as activated protein C
resistance (APC-R) negative,
heterozygous and homozygous
according to factor Va mutation
(VaQ506) gene testing. Individual
values of activated protein C
(APC) ratio are plotted for each
group.
Prevalence and clinical profile of thrombotic patients
regarding APC resistance
A total of 126 patients with thromboembolic disease
were analysed: their mean age was 41 years (range,
16 to 80) at the time of inclusion. Twenty-two per
cent exhibited an APC resistance: 4% were homo-
zygous and 18% were heterozygous for factor V
mutation (Table 1). The clinical profile of the patients
is summarized in Table 1. The mean age at the time
of first thrombotic episode did not differ between
APC-R positive and negative patients : they were 41
years (range, 21 to 69) and 40 years (range, 16 to
78), respectively. The APC-R homozygous patients
suffered a first thrombotic event at a younger age but
because of the small number of patients the difference
was not statistically significant. The type of pres-
entation of the thromboembolic manifestation was
similar in both groups with a predominance of
proximal deep vein thrombosis. Moreover, the pres-
ence of either symptomatic or asymptomatic lung
embolism was assessed in 101 patients : the overall
prevalence of lung embolism was 38% (38 out of
101 patients) with no significant difference between
APC-R positive (24%, 5 out of 21 patients) and
negative patients (41%, 33 out of 80). A striking
preponderance of females was found in both the
overall population and the APC-R-negative group
while the sex ratio completely inverted in the APC-R-
positive group which displayed a slight prepon-
derance of males (P!0±02). A familial history was
highly predictive of APC resistance as it was found in
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Table 1 Clinical profile of patients with thromboembolic disease
APC-R positive
APC-R
Overall Total Homozygous Heterozygous negative P
Healthy controls
Number 91 3 0 3 88 —
Sex (male}female) 37}54 1}2 0 1}2 36}52 —
Thromboembolic patients
Number 126 28 5 23 98 —
Sex (male}female) 41}85 15}13 3}2 12}11 26}72 !0±02
Mean age at 1st thrombotic event (years) 40 41 33 43 40 NS
Presenting thrombotic event
Proximal DVT 63 16 4 12 47 —
Distal DVT 53 11 1 10 42 —
Lung embolism 5 0 0 0 5 —
Varia 5 1 0 1 4 —
No. of patients with positive family history
of thromboembolic disease (%)
38 (30%) 16 (57%) 4 (80%) 12 (52%) 22 (22%) !0±001
No. of patients with recurrence of
thromboembolic disease (%)
49 (39%) 16 (57%) 2 (40%) 14 (61%) 33 (34%) !0±05
No. of patients with predisposing risk
factors
83 (66%) 16 (57%) 4 (80%) 12 (52%) 67 (68%) NS
APC-R, activated protein C resistance; DVT, deep vein thrombosis ; NS, not significant.
Table 2 Prevalence of predisposing factors in patients with thromboembolic disease
APC-R positive
APC-R
Thromboembolic patients Overall Total Homozygous Heterozygous negative
Number 126 28 5 23 98
No. of patients with predisposing risk factors
Total 83 (66%) 16 (57%) 4 (80%) 12 (52%) 67 (68%)
Hormonotherapy 15 3 1 2 12
Other haemostatic abnormalities 13 1 0 1 12
Traumatism 12 2 0 2 10
Post-partum 13 3 1 2 10
Immobilization 9 2 2 0 7
Varices 9 1 0 1 8
Postoperative state 6 3 0 3 3
Inflammatory disease 3 0 0 0 3
Neoplastic disease 3 1 0 1 2
APC-R, activated protein C resistance.
57% of APC-R-positive patients but only 22% of
APC-R-negative patients (P!0±001). The recur-
rence rate was higher among APC-R-positive patients
(odds ratio : 2±6; P!0±05). The percentage of
patients for which another predisposing factor was
identified was quite similar in APC-R-positive (57%)
and negative (68%) groups. Likewise, the prevalence
of risk factors analysed individually was grossly
equivalent for the APC-R positive and negative
thrombotic populations (Table 2). The multivariate
analysis demonstrates that familial history (odds
ratio : 4±5; P!0±002) and male sex (odds ratio : 3±1;
P!0±02) were two independent predictors of APC
resistance. On the other side, APC-R was significantly
associated with recurrences in our population.
Analysis of in- and outpatients
As the study population included both outpatients
attending a phlebology clinics and hospitalized
patients, we combined both subgroups in a Mantel-
Haenszel’s test regarding the clinical characteristics
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Table 3 Comparison of in- and outpatients with thromboembolic disease
Inpatients Outpatients
Total
APC-R
positive
APC-R
negative Total
APC-R
positive
APC-R
negative
Number of patients 28 7 21 98 21 77
Sex (male}female) 15}13 6}1 9}12 26}72 9}12 17}60
Mean age (years) at 1st thrombotic event 53 47 55 36 39 35
Presenting thrombotic event
Proximal DVT 23 5 18 40 11 29
Distal DVT 3 1 2 50 10 40
Lung embolism 1 0 1 4 0 4
Varia 1 1 0 4 0 4
No. of patients with positive family
history of thromboembolic disease (%)
7 (25%) 5 (71%) 2 (10%) 31 (32%) 11 (52%) 20 (26%)
No. of patients with recurrence of
thromboembolic disease (%)
13 (46%) 4 (57%) 9 (43%) 36 (37%) 12 (57%) 24 (31%)
APC-R, activated protein C resistance.
associated with APC-R. The relationship between
APC-R and the sex ratio (P!0±02), the familial
history (P!0±001) and the rate of recurrence
(P!0±05) was confirmed independently from the
stratification (Table 3).
Discussion
We conducted a prospective study of APC resistance
(APC-R) in thromboembolic patients and healthy
control subjects attending one Belgian academic
hospital. Patients and controls were tested for APC-
R by both APC ratio coagulation assay and gene
analysis of factor V mutation (F Va Q506). The
APC ratio discriminates accurately between APC-R
negative, heterozygous and homozygous subjects
although results of the APC ratio assay shows some
overlap between the three groups. When using a cut-
off of 2±6, the APC ratio provided, in our series, a
sensitivity of 79% and a specificity of 96%. The APC
ratio determination can be further refined using
a modified test that confers increased sensitivity
and specificity and allows APC ratio assessment
in individuals currently receiving coumadine
derivatives or bearing a lupus anticoagulant [24–26].
This method was not yet available at the beginning
of the study.
The frequency of APC-R found in our
thromboembolic patients (22%) and controls (3±3%)
is in concordance with the results reported in the
literature. As previously recalled, the values suffer
large variations depending on ethnic groups, APC-R
assay, patients’ selection and associated risk factors
[27–28]. The figure of 22% is close to the results
found in both the large Leiden study (21%) [8] and
French (17%) [29–30] and Australian (27%) [31]
reports. Figures as high as 50 to 60% were obtained
in small series generally selected with restrictive
criteria such as young age and absence of classical
risk factors [15].
Regarding APC resistance, the clinical profiles of
thrombotic patients raise pertinent issues. In an
individual patient, the most powerful clinical
predictors of APC-R are a family history of
thromboembolism, and male sex. As APC-R has been
firmly established as an autosomal dominant trait
[32], the first point is quite plausible even if it has not
been found in some other studies [29]. The second
finding is rather more intriguing. In fact, the female
preponderance found in the whole cohort is inverted
in the APC-R positive subgroups. The high proportion
of women in our thromboembolic population
reflected the preponderance of female patients
attending phlebology clinics whereas the in-patient
subgroup involved males and females in similar
proportions. A potential bias in the analysis was
discarded by performing a Mantel-Haenszel test
after stratification for both subgroups (in- and
outpatients). This test confirmed the over-represen-
tation of males among APC-R positive patients. Thus,
the relationship between APC-R and male sex was
found to be independent of the subgroups. The result
is hardly compared with other studies as either they
included a limited number of male patients or they
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did not address the link between the sex ratio and
APC-R. One can speculate that APC-R weakens the
influence of hormonotherapy as a causative agent
of thromboembolism. Whatever, it must be stressed
that APC-R is only one risk factor for throm-
boembolism alongside other precipitating circum-
stances. Associated predisposing factors were found
in APC-R positive as frequently as in APC-R negative
patients underlying the fact that APC-R is probably
only a weak thrombogenic factor acting together
with other stimuli. In accordance with previous
reports [29], the age at the time of the first thrombotic
episode was not significantly different between APC-
R positive and negative. One exception is the homo-
zygous patients who develop the first thrombotic
event at an earlier age but the small number of
homozygous patients in our series precludes firm
conclusions. Interestingly APC resistance did not
influence the location or the severity of thrombotic
disorder. The proportion of either symptomatic or
asymptomatic lung embolism was similar in APC-R
positive and APC-R negative patients. Finally, the
rate of recurrence was also found to be higher among
APC-R positive patients. It must be recalled, however,
that the recurrences were not assessed prospectively
but were established according to the medical chart
obtained at enrollment. However, as the age at the
first thrombotic event was identical for APC-R
positive and negative patients, the analysis probably
remains valid in spite of the retrospective design. This
issue was not addressed in other large studies since
relapsing patients were generally excluded [8, 29].
Multivariate analysis confirm that both factors,
i.e. male sex and family history, were independent
predictors of APC resistance. Reciprocally, APC-R is
significantly associated with recurrence.
In conclusion, we confirmed in a prospective study
using APC-R ratio and gene testing of factor V
mutation that APC resistance is a frequent risk factor
of thromboembolism. The clinical profile of patients
highlights that APC-R positive thrombotic patients
more frequently exhibit a positive family history and
recurrences of thrombosis. Additionally, APC-R-
related thromboembolism affects male patients as
frequently as females. APC-R should be looked for
since the findings may be helpful for genetic
counselling and appropriate therapy management,
at least in relapsing patients.
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